PARP1 and neoplasm: Therapeutically, exploiting this dependency using DDR-targeted agents (ATM, ATR, DNA-PKcs, or PARP inhibitors) is a promising strategy to overcome resistance, as it can tip the balance between the extensive DNA damage induced by SBRT and the tumor’s capacity to repair it.